Anti-anthrax monoclonal antibodies - IQ Therapeutics

Drug Profile

Anti-anthrax monoclonal antibodies - IQ Therapeutics

Alternative Names: Anthraxumab; anti-LF; anti-PA; IQ-DAA; IQ-NLF; IQ-NPA; IQNLF-1

Latest Information Update: 29 Apr 2011

Price : $50

At a glance

  • Originator IQ Therapeutics
  • Class Antibacterials; Monoclonal antibodies
  • Mechanism of Action Anthrax toxin inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

    No

Highest Development Phases

  • Phase I Anthrax

Most Recent Events

  • 26 Apr 2011 IQ Therapeutics completes enrolment in its phase I trial for Anthrax (in volunteers) in the Netherlands
  • 24 Feb 2011 Phase-I clinical trials in Anthrax (in volunteers) in Netherlands (Injection)
  • 05 Mar 2008 Preclinical development is ongoing
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top